Home Cart Sign in  
Chemical Structure| 2765081-21-6 Chemical Structure| 2765081-21-6

Structure of RMC-6236
CAS No.: 2765081-21-6

Chemical Structure| 2765081-21-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RAS-IN-2 is an effective RAS(ON)MULTI inhibitor used in cancer research.

Synonyms: Daraxonrasib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RMC-6236

CAS No. :2765081-21-6
Formula : C44H58N8O5S
M.W : 811.05
SMILES Code : CC(COC([C@H]1NN(C([C@H](CC2=NC3=CS2)NC([C@H]4C[C@@H]4C)=O)=O)CCC1)=O)(C)CC5=[C@@](N(CC)C6=C5C=C3C=C6)[C@@]7=C([C@H](C)OC)N=CC(N8CCN(C)CC8)=C7
Synonyms :
Daraxonrasib
MDL No. :N/A

Safety of RMC-6236

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of RMC-6236

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HPAC cells 1.2 nM (EC50) 48 hours To assess the impact of RMC-6236 on RAS pathway signaling in HPAC cells. Results showed sustained inhibition of pERK and pS6 and induction of apoptosis. PMID: 38593348
Capan-2 cells 1.4 nM (EC50) 48 hours To assess the impact of RMC-6236 on RAS pathway signaling in Capan-2 cells. Results showed sustained inhibition of pERK and pS6. PMID: 38593348
6419c5 or 2838c3 tumor cells 100nM 48 hours To assess the effect of RMC-6236 on MHC-I expression in tumor cells. Results showed that MHC-I expression was upregulated in tumor cells treated with RMC-6236. PMID: 40057911

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Capan-2 xenograft model Oral gavage 3, 10, or 25 mg/kg Single dose or daily for 28 days To assess the pharmacokinetic, pharmacodynamic, and antitumor activity of RMC-6236 in Capan-2 xenograft models. Results showed dose-dependent tumor regression and sustained RAS pathway inhibition. PMID: 38593348
C57BL/6 mice Subcutaneous and orthotopic PDAC models Oral gavage 25 mg/kg Once daily for 7 days To evaluate the anti-tumor activity of RMC-6236 in PDAC models. Results showed that RMC-6236 led to tumor regressions and increased T cell infiltration in the tumor microenvironment. PMID: 40057911

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05379985 Non-small Cell Lung Cancer (NS... More >>CLC)|Colorectal Cancer (CRC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Advanced Solid Tumors Less << PHASE1 RECRUITING 2026-06-30 UC Irvine/Chao Family Comprehe... More >>nsive Cancer Center, Orange, California, 92868, United States|UCLA, Santa Monica, California, 90404, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Perlmutter Cancer Center at NYU Langone Health, New York, New York, 10016, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Columbia University, New York, New York, 10032, United States|Christ Hospital Cancer Center, Cincinnati, Ohio, 45219, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|University of Texas at Austin, Austin, Texas, 78712, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Next Oncology, San Antonio, Texas, 78229, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Next Oncology Virginia, Fairfax, Virginia, 22031, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.23mL

0.25mL

0.12mL

6.16mL

1.23mL

0.62mL

12.33mL

2.47mL

1.23mL

 

Historical Records

Categories